- Neuropsychiatrist, with joint appointments in psychiatry and neurology, and adjunct faculty member at Johns Hopkins School of Medicine
- Former chief psychiatric consultant to the Johns Hopkins Multiple Sclerosis and Transverse Myelitis centers
- Researches the biological basis of depression and dementia and looks for new ways to diagnose, predict, and treat these diseases
- Has investigated the effects of the immune system on mood regulation and cognition, and provided neuropsychiatric care to patients with comorbidities such as depression and cognitive impairment
- Chief scientific officer of MyMD Pharmaceuticals
Adam Kaplin, M.D., is a practicing neuropsychiatrist and an assistant professor in the department of psychiatry, division of neuropsychiatry, at Johns Hopkins School of Medicine.
Kaplin was formerly the chief psychiatric consultant to the Johns Hopkins Multiple Sclerosis and Transverse Myelitis centers. There, he investigated the biological basis of the effects of the immune system on mood regulation and cognition, and he provided neuropsychiatric care. His research is focused on understanding how biological factors contribute to depression and dementia and on discovering new ways to diagnose, predict, and treat these diseases.
Kaplin has investigated the connection between the immune system and depression and cognitive impairment in people with multiple sclerosis (MS) and MS spectrum diseases. He has taken special interest in reducing rates of suicide in people with MS and has become involved in using virtual technology to help identify those at risk and to prevent suicide.
“Health information technology is on the verge of revolutionizing medical care and research, and I believe that for clinical researchers to not be involved in its development and implementation is akin to missing the molecular biological revolution of the mid-20th century,” Kaplin says.
Kaplin has recently transitioned to working in the pharmaceutical industry as the chief scientific officer of MyMD Pharmaceuticals, a company that’s developing therapeutics for a range of autoimmune diseases and immune-mediated neuropsychiatric illnesses.
“My work in MS treating patients with depression and cognitive impairment impressed upon me the need to develop novel therapeutics because of the limitations of existing treatments, especially when I started over a decade ago,” Kaplin says. “This led me to engage in studies of drugs such as esketamine, which has been shown to have potent anti-inflammatory effects both preclinically and in patients.”
Kaplin completed his undergraduate training at Yale University and received his medical degree and doctorate in neuroscience from the Johns Hopkins School of Medicine. His research training experience includes working in the labs of two Nobel laureates. He completed his doctorate in neuroscience and postdoctoral training in the lab of Solomon Snyder, M.D., who was the 2005 recipient of the National Medal of Science (the highest science honor in the United States).
Affiliations and Publications
- Nancy Davis Race to Erase MS panelist
- Cure Addiction Now research scientist
- AnthroTronix adviser
- EMD Serono MS Advisory Committee
- Multiple Sclerosis Association of America adviser
- Joint Artificial Intelligence Center task force on suicide prevention in the military
- National Network of Depression Centers task force on ketamine
- Montel Williams MS Foundation head of Scientific Advisory Board
- Published more than 60 peer-reviewed articles and contributed to 14 chapters in internationally recognized journals and textbooks, including Cell, Nature Clinical Practice Neurology, Translational Psychiatry, The Lancet Respiratory Medicine, The New Oxford Textbook of Psychiatry, and Kaplan and Sadock's Comprehensive Textbook of Psychiatry
Experts are medical professionals who have been engaged by Kopa to provide information and support to our users. Posts from Experts are not medical advice and do not represent the position of Kopa.